Overview
Amagma Therapeutics is dedicated to developing antibody therapeutics against inflammatory diseases which have proven to be intractable by other approaches. A number of these serious illnesses are driven by overactive extracellular proteases which can compromise organ function and fuel inflammation. Small molecule approaches targeting this class of proteins have proven to be challenging due to off target effects. Using our precision-targeted antibody approach, we are developing therapies that combine efficacy and safety.